
Enabling Surge Production: Meet The CEO Who Has Done It
Technicians working in a laboratory
getty
With uncertainty about tariffs and other government policies growing, companies need more flexibility in their operations. That is, they need to ability to surge production quickly, as they also need the capability to cut costs quickly. President Trump's tariffs and likely retaliation provide extreme cases where this may be necessary. Companies without access to inexpensive raw materials may have to hunker down. But other businesses may see opportunity as foreign competitors become uncompetitive.
Most business leaders understand cost-cutting well, but ramping up production—especially quickly and without damaging quality—is more a black art. Thus the benefit of looking deeper into the topic.
Fred Turner, CEO Curative
KELLY BAUCH
Fred Turner, the founder and CEO of Curative, has ramped up quickly and ramped up slowly, as well as pivoted to different lines of business. His methods are not so much a roadmap for other business leaders as an idea map. That is, his experience highlights a way of thinking that can help others determine their own solutions to their particular challenges.
Before trying to gain flexibility, though, business leaders should consult my guide for how to know when increased supply flexibility is important. The need for quickly changing production capacity comes from the economic concept of demand elasticity. Sometimes the demand for a particular good or service changes quickly. When that happens, producers that can quickly meet the demand will profit. But when demand falls, those who cannot cut costs quickly will face severe problems.
Turner faced the challenge of rapidly rising demand in the middle of the pandemic. His business was testing for sepsis, a serious condition in which the body reacts improperly to an infection. The Covid pandemic hit in the company's first year of business, and Turner realized that they had the capability to provide Covid testing. That pivot meant a huge increase in demand.
Looking at constraints was one key element of the game plan, Turner explained to me on a video call. Laboratory capacity was much lower than swabbing capacity. If they administered as many tests as possible, they would create a backup in the laboratory, delaying test results by days. But test results that take a week to get back from the lab were not very useful. So the company throttled back on swabbing. They matched the throughput available at the bottleneck: the lab. Turner cites the classic book, The Goal, by Eliyahu Goldratt. (My own copy was close at hand, and Turner grinned when I held it up to the camera.) Goldratt's theory of constraints led to a focus on different parts of the process that held up throughput.
Later, times swabs were in short supply. Turner argues for 'orthogonal supply chains.' He describes this concept as not trying to compete for the same materials that everyone else is trying to buy. His team found an alternative product that would work, got it certified, and satisfied demand.
This approach works best, Turner says, with end-to-end control of the software. Leadership needs to understand the bottlenecks in the overall process. If data at various stages of production are not up-to-date and accessible simultaneously, then the management team cannot diagnose problems.
Predicting demand surges is not always possible, but Turner's company developed a great solution. The lab test for Covid is usually presented as a positive or negative, but the lab knows the level of infection, called viral load. Those results are usually not useful for an individual, Turner said. In the aggregate, however, the average viral load at a testing location predicts future demand for tests. Viral load probably predicted infection rates, which in turn predicted test demand.
The Covid testing was a great example of rapid ramp-up, but our conversation shifted to a planned ramp-up. Curative is currently offering group health care insurance with no deductible and no co-pays. That presented the company with two potential bottlenecks: finding staff for the member on-boarding process, and finding healthcare providers for the group members. The resolution was controlled growth. The company asks every member to join a video call about how their unique system works. That causes a need for many people in January, the most common time for health plan changes. Normal hiring of employees by their client companies is spread more evenly through the year, but adding a large number of employees from a single company causes a surge of demand for onboarding appointments. Curative's solution is to carefully control their pace of growth.
Controlling growth comes through pricing, Turner says. They look for the sweet spot, whereby the pricing leads to profitability with growth, but not so much growth that service suffers.
Another tool for growing rapidly with less stress on production capacity is allowing no customization of plans. Large employers may ask for a plan with some details changed from the usual offering. That raises the difficulty level for health procedure authorizations, which also leads to more mistakes, leading to more correction work. As Turner explained this, I recalled the headaches of a bank trust department with a large number of special employee benefit plans. Customized plans were the major source of errors at the large bank where I used to work.
Summarizing Fred Turner's lessons as I understood them, business leaders should begin with viewing the process as a whole. Having good data from start to finish is crucial. If not a single software platform, as Turner suggests, then work to get the different systems to share data seamlessly and in real time.
With data in hand, identifying bottlenecks begins the ramp-up process. Then anticipating subsequent bottlenecks will be necessary. Predicting surges, though difficult, will help tremendously.
At times, throttling back demand will be critical to good service to those you serve. You'll certainly want to ramp up production, but don't sell more than you can with good service.
Finally, when a particular product or service that is a necessary input becomes hard to buy, look orthogonally—in a different direction—for another product that might do the job.
And although Turner did not specify it, a can-do attitude seems to permeate his experience, especially when the market asks a CEO to surge production.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Zakai Zeigler's prelimiary injunction challenging NCAA redshirt rule for fifth year of eligibility denied
Several weeks after Zakai Zeigler filed a lawsuit against the NCAA seeking a fifth year of eligibility, his preliminary injunction has been denied, according to Yahoo Sports' Ross Dellenger. Zeigler had already played four seasons for Tennessee and didn't begin his college career until 2021, one year after the 2020-21 class that was allowed one more year of eligibility lost during the COVID-19 pandemic. Advertisement In the lawsuit, filed in the Eastern District Court of Tennessee, Zeigler was looking to play the 2025-26 season, challenging the NCAA rule that an athlete has four years of eligibility within a five-year window. Zeigler, 22, isn't allowed an opportunity to earn NIL money for a fifth year because he used up all of his eligibility. As the lawsuit argues, that deprives him of a fifth year, "the most lucrative year of the eligibility window for the vast majority of athletes." How lucrative? The lawsuit argued that Zeigler could earn between $2 million and $4 million in a fifth year based on his record of success and visibility playing in the SEC. Those figures are projections from the Spyre Sports Group, which facilitates Tennessee's NIL collective. Advertisement Athletes who receive a redshirt are allowed a fifth year of eligibility, which gives them one more year to earn NIL income. A freshman who was redshirted, for example, would still be able to earn NIL money even if he or she doesn't play. As the filing, the documents of which were posted online by Boise State professor Sam Ehrlich, reads: "Many players, however, do compete in the fifth year of their eligibility window. And they can earn NIL compensation for all five of those years. Had Zeigler been withheld from competing in sports during one of those four years, perhaps by redshirting, the NCAA rules would permit him to participate again next year. And this is true even if he would have slowed his academic progress and taken five years to graduate." Zeigler graduated in May, majoring in retail and merchandising management. This is different from the lawsuit Vanderbilt quarterback Diego Pavia filed against the NCAA, claiming that he should be allowed a fifth year of eligibility because he played his first two years for New Mexico Military Institute, a junior college. In December, Pavia was granted an injunction allowing him to play the 2025 college football season. Advertisement Last season with the Vols, the 5-foot-9 Zeigler averaged 13.6 points, 7.4 assists and 1.9 steals while shooting 32% on 122 3-point attempts. He was named a third-team All-American, and won first-team All-SEC and SEC defensive player of the year honors for two consecutive seasons. The Volunteers finished 30-8, 12-6 in the SEC, and advanced to the NCAA tournament's Elite Eight before losing to Houston. Zeigler holds the Tennessee single-season (275) and career (747) records for assists, and career steals with 251.


Forbes
an hour ago
- Forbes
Global Gender Gap Shrinks But Parity Is Still More Than A Century Away
The gender gap around the world is closing at its fastest pace since before the Covid-19 pandemic. But even at the current rate of progress, full parity is well over a hundred years away, new research reveals. According to the 19th edition of the World Economic Forum's annual Global Gender Gap Report, the gap across 148 economies around the world now stands at 68.8% when examining factors including economic opportunities, education, health, and political leadership. When looking at the 145 economies that were examined both this year and last, the gender gap contracted by 0.3 percentage points in 2025—from 68.4% in 2024. That marked the fastest annual contraction since before Covid-19 spread around the world in 2020, stalling or even revering progress on many metrics, such as women's labor force participation, in some countries. Despite this uptick, however, and based on the WEF's calculations, it will still take 123 years to reach full parity in gender globally, and that's assuming today's pace of progress doesn't slacken. 'The progress made in this edition was driven primarily by significant strides in political empowerment and economic participation, while educational attainment and health and survival maintained near-parity levels above 95%,' the authors of the report write. They add, however, that even though women today represent 41.2% of the global paid workforce, 'a stark leadership gap persists with women holding only 28.8% of top leadership positions.' The 2025 report showed that, while no economy has yet achieved full gender parity, some are getting closer. For a 16th consecutive year, for example, Iceland led the index with the smallest gender gap of just 92.6%. Indeed, Iceland is the only economy to have closed more than 90% of its gender gap. The country's northern European neighbors—Finland, Norway and Sweden—have all closed more than 80% of their gap and have also consistently ranked in the top 10 in every edition of the report since 2006. Other countries in this year's top 10 include the United Kingdom, the Republic of Moldova, Germany, Ireland, New Zealand and Namibia. Overall, the authors of the report note that there's a slight correlation between the current income levels of the countries covered and their gender gaps, with richer economies being marginally more gender equal. At the aggregate level, the authors note, economies considered to be high-income have closed 74.3% of their gender gap, which is slightly more than the averages observed across lower income countries. The authors emphasize, however, that this correlation 'is low and does not indicate causation.' In other words, being a high-income nation does not automatically mean that gender gaps are smaller.
Yahoo
an hour ago
- Yahoo
COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments
BioNTech is buying fellow German firm CureVac for approximately $1.25 billion as the COVID-19 vaccine maker moves to expand into cancer treatments. For each CureVac share they own, investors will get about $5.46 worth of BioNTech American Depositary Shares. CureVac is developing cancer medicines using the same mRNA technology that BioNTech uses for its COVID-19 (CVAC) shares skyrocketed 37% Thursday when the biotech company agreed to be bought by COVID-19 vaccine maker and fellow German firm BioNTech (BNTX) in an all-stock deal valued at about $1.25 billion. The purchase boosts BioNTech's move into producing new cancer treatments. CureVac said its investors will receive approximately $5.46 worth of BioNTech American Depositary Shares for each CureVac share they own. That a 34% premium to yesterday's closing price. The company noted it is "developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid ("mRNA")." BioNTech's COVID-19 shot is also mRNA-based. BioNTech co-founder and CEO Dr. Ugur Sahin said the deal is aimed at "advancing the development of innovative and transformative cancer treatments and establishing new standards of care for various types of cancer in the coming years." The transaction is expected to close this year and would see CureVac's operating subsidiary become a wholly owned subsidiary of BioNTech. Shares of CureVac soared to their highest level since December 2023. U.S.-listed shares of BioNTech were little changed and remain down nearly 8% year-to-date. Read the original article on Investopedia 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤